Ocera Therapeutics Appoints Chief Development Officer

From DCAT Value Chain Insights (VCI)

By People On The Move posted 08-13-2014 11:42

Ocera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, has appointed  Raji Patni, MD, as chief development officer, effective September 2, 2014.

Prior to joining Ocera, Dr. Patni served as senior vice president for Actelion US Prior to his time at Actelion, Dr. Patni served as vice president at Roche as well as in leadership positions at Novartis and Pfizer.

‚ÄčOcera is focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and fast track status by the US Food and Drug Administration for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.

Source: Ocera Therapeutics

Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription